Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older

Outcomes in older patients with Hodgkin lymphoma (HL) tend to be poor following conventional chemotherapy regimens. Treatment-related toxicity is significant and comorbidities often limit therapeutic options. This phase 2, open-label study evaluated the efficacy and safety of brentuximab vedotin, a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Forero-Torres, Andres, Holkova, Beata, Goldschmidt, Jerome, Chen, Robert, Olsen, Gregg, Boccia, Ralph V., Bordoni, Rodolfo E., Friedberg, Jonathan W., Sharman, Jeff P., Palanca-Wessels, Maria Corinna, Wang, Yinghui, Yasenchak, Christopher A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2015
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4692140/
https://ncbi.nlm.nih.gov/pubmed/26377597
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-06-644336
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados